The broad support of testing for BNP or NT-proBNP is in recognition of the fact that when controlling for extensive covariates, the mere presence of a BNP or NT-proBNP above modest thresholds (e.g. BNP >30 ng/L or NT-proBNP >125 ng/L) is associated with heightened risk for progression to symptomatic (Stages C/D) HF and further reduces disparity in HF risk prediction for certain groups (including women and Black individuals). Here, NPPB is linked to hydrops fetalis.